ArtaninCAS# 96917-26-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 96917-26-9 | SDF | Download SDF |
| PubChem ID | 14841901 | Appearance | Cryst. |
| Formula | C16H18O5 | M.Wt | 290.3 |
| Type of Compound | Coumarins | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 5,7-dimethoxy-8-(3-methylbut-2-enoxy)chromen-2-one | ||
| SMILES | CC(=CCOC1=C(C=C(C2=C1OC(=O)C=C2)OC)OC)C | ||
| Standard InChIKey | BSOMOYSKROCRIG-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Artanin displays promising inhibition against both MSSA and MRSA with minimal inhibitory concentrations (MICs) of 8-64 ug/ml, but very weak against Gram-negative pathogen and yeast with MICs of 256 to ≥1024 ug/ml. |
| Targets | Antifection |
Artanin Dilution Calculator
Artanin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4447 mL | 17.2236 mL | 34.4471 mL | 68.8942 mL | 86.1178 mL |
| 5 mM | 0.6889 mL | 3.4447 mL | 6.8894 mL | 13.7788 mL | 17.2236 mL |
| 10 mM | 0.3445 mL | 1.7224 mL | 3.4447 mL | 6.8894 mL | 8.6118 mL |
| 50 mM | 0.0689 mL | 0.3445 mL | 0.6889 mL | 1.3779 mL | 1.7224 mL |
| 100 mM | 0.0344 mL | 0.1722 mL | 0.3445 mL | 0.6889 mL | 0.8612 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Cyproheptadine hydrochloride
Catalog No.:BCC5161
CAS No.:969-33-5
- 1,2-Bis(4'-methyl-2,2'-bipyridin-4-yl)ethane
Catalog No.:BCC8414
CAS No.:96897-04-0
- Nyasol
Catalog No.:BCN7579
CAS No.:96895-25-9
- VIP (guinea pig)
Catalog No.:BCC5725
CAS No.:96886-24-7
- XAC
Catalog No.:BCC7600
CAS No.:96865-92-8
- XCC
Catalog No.:BCC7890
CAS No.:96865-83-7
- Maoecrystal A
Catalog No.:BCN5407
CAS No.:96850-30-5
- Maoecrystal B
Catalog No.:BCN4516
CAS No.:96850-29-2
- 8beta-Tigloyloxycostunolide
Catalog No.:BCN7115
CAS No.:96850-21-4
- Indatraline hydrochloride
Catalog No.:BCC7123
CAS No.:96850-13-4
- Przewaquinone C
Catalog No.:BCN3003
CAS No.:96839-29-1
- Orlistat
Catalog No.:BCC3830
CAS No.:96829-58-2
- Cisatracurium Besylate
Catalog No.:BCC4345
CAS No.:96946-42-8
- Momordin Ic
Catalog No.:BCN1216
CAS No.:96990-18-0
- DTG
Catalog No.:BCC6812
CAS No.:97-39-2
- Eugenol
Catalog No.:BCN5964
CAS No.:97-53-0
- Isoeugenol
Catalog No.:BCN8312
CAS No.:97-54-1
- Solvent Yellow 3
Catalog No.:BCC9150
CAS No.:97-56-3
- Allantoin
Catalog No.:BCN4527
CAS No.:97-59-6
- 2-Methylvaleric acid
Catalog No.:BCN8498
CAS No.:97-61-0
- Ac-Ala-OH
Catalog No.:BCC3189
CAS No.:97-69-8
- Disulfiram
Catalog No.:BCC2098
CAS No.:97-77-8
- (+)-Gallocatechin
Catalog No.:BCN5928
CAS No.:970-73-0
- (-)-Epigallocatechin(EGC)
Catalog No.:BCN4519
CAS No.:970-74-1
Synergism of coumarins from the Chinese drug Zanthoxylum nitidum with antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).[Pubmed:27912884]
Phytomedicine. 2016 Dec 15;23(14):1814-1820.
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious therapeutic challenge in current clinic and new drug development. Natural coumarins have diverse bioactivities and the potential of resistance modifying effects. PURPOSE: This study is to present in-depth evaluations of in vitro antimicrobial activities of four natural coumarins 5-geranyloxy-7-methoxycoumarin (Gm, 1), (5,7-dimethoxy-8-prenyloxycoumarin (Artanin, Ar, 2)), isopimpinellin (Is, 3) and phellopterin (Ph, 4) from Zanthoxylum nitidum (Roxb.) DC. (Rutaceae) extracts, focusing on their potential restoration the activity of conventional antibacterial agents against clinical MRSA strains. METHODS: Bioactivity-guided fractionation and spectral analyses were used to isolate the coumarins and identify the structures, respectively. The double broth microdilution method was used to assay the coumarins' alone activity. The classic checkerboard microdilution and dynamic time-killing methods were used to evaluate combinatory effects. RESULTS: The four plant coumarins Gm (1), Ar (2), Is (3) and Ph (4) were isolated and identified from Z. nitidum extracts. Coumarins 1-4 displayed promising inhibition against both MSSA and MRSA with minimal inhibitory concentrations (MICs) of 8-64microg/ml, but very weak against Gram-negative pathogen and yeast with MICs of 256 to >/=1024microg/ml. The geranyloxy and prenyloxy substitutions showed to be more active than the methoxy substitution on the coumarin skeletons. 1-4 also showing different extent of synergism with a total of eight conventional antibacterial agents, i.e. chloramphenicol (CL), gentamicin (CN), fosfomycin (FF), levofloxacin (LE), minocycline (MI), piperacillin/tazobactam (P/T), teicoplanin (TE) and vancomycin (VA) against ten clinical MRSA strains. Four to ten of the tested MRSA strains showed bacteriostatic synergy in the eleven combinations. The anti-MRSA modifying effects were related to different arrangement in the combinations with fractional inhibitory concentration indices (FICIs) from 0.187 to 1.125 and the three combinations CN (Is), CL (Ph) and MI (Gm) were the best ones. The enhancement of activity was also shown by 2-64 of dose reduction indices (DRIs) of the combined MICs, with VA (Ph) combination resulted the biggest DRI. The resistance of MRSA to antibacterial agents could be reversed in the combinations of CL (Gm or Ph), LE (Ph) and MI (Is) following the Clinical and Laboratory Standards Institute (CLSI) criteria. Six combinations P/T (Gm), TE (Ar), CN (Is), VA (Ph) and CL (Gm or Ph) also showed bactericidal synergy with Deltalog10CFU/ml >2 at 24h incubation. CONCLUSIONS: The coumarins showed high potentiating effects of the antibacterial agents against multi-drug resistant SA. The resistance reversal effect of CL, LE and MI warrants further pharmacological investigation on combinatory therapy for the sake of fighting against MRSA infections.
